1. 20 ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT. (18th January 2018) Authors: Peyrin-Biroulet, Laurent; Rubin, David T; Feagan, Brian; Oh, Young S; Arulmani, Udayasankar; Tyrrell, Helen; Maciuca, Romeo; Williams, Sarah; Tole, Swati; Thommes, James Journal: Inflammatory bowel diseases Issue: Volume 24(2018)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Combatting mucosal melanoma: recent advances and future perspectives. (8th October 2018) Authors: Tyrrell, Helen; Payne, Miranda Journal: Melanoma management Issue: Volume 5:Number 3(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Combatting mucosal melanoma: recent advances and future perspectives. (8th October 2018) Authors: Tyrrell, Helen; Payne, Miranda Journal: Melanoma management Issue: Volume 5:Number 3(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Combatting mucosal melanoma: recent advances and future perspectives. (8th October 2018) Authors: Tyrrell, Helen; Payne, Miranda Journal: Melanoma management Issue: Volume 5:Number 3(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. (January 2022) Authors: Vermeire, Severine; Lakatos, Peter L; Ritter, Timothy; Hanauer, Stephen; Bressler, Brian; Khanna, Reena; Isaacs, Kim; Shah, Saumin; Kadva, Alysha; Tyrrell, Helen; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Eden, Christopher; Zhang, Wenhui; Feagan, Brian G; Abraham, Philip; Acir Crip... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. (February 2022) Authors: Danese, Silvio; Colombel, Jean-Frederic; Lukas, Milan; Gisbert, Javier P; D'Haens, Geert; Hayee, Bu'hussain; Panaccione, Remo; Kim, Hyun-Soo; Reinisch, Walter; Tyrrell, Helen; Oh, Young S; Tole, Swati; Chai, Akiko; Chamberlain-James, Kirsten; Tang, Meina Tao; Schreiber, Stefan; Aboo, Nazimuddin; ... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 2(2022) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PWE-071 Etrolizumab induction in moderate/severe anti-TNF intolerant/refractory (IR) UC: the hickory open-label induction (OLI) trial. (8th June 2018) Authors: Hayee, Bu'hussain; Rubin, David; Feagan, Brian; Oh, Young S; Arulmani, Udayasankar; Tyrrell, Helen; Maciuca, Romeo; Williams, Sarah; Tole, Swati; Thommes, James; Peyrin-Biroulet, Lauren Journal: Gut Issue: Volume 67(2018)Supplement 1 Page Start: A102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Salvaging a prison needle and syringe program trial in Australia requires leadership and respect for evidence. Issue 8 (19th October 2015) Authors: Stoové, Mark; Treloar, Carla J; Maher, Lisa; Tyrrell, Helen; Wallace, Jack Journal: Medical journal of Australia Issue: Volume 203:Issue 8(2015) Page Start: 319 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗